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Abstract
We have constructed and evaluated the utility of a helper-dependent virus vector system that is
derived from Human Cytomegalovirus (HCMV). This vector is based on the herpes simplex virus
(HSV) amplicon system and contains the HCMV orthologs of the two cis-acting functions required
for replication and packaging of HSV genomes, the complex HCMV viral DNA replication origin
(oriLyt), and the cleavage packaging signal (the a sequence). The HCMV amplicon vector replicated
independently and was packaged into infectious virions in the presence of helper virus. This vector
is capable of delivering and expressing foreign genes in infected cells including progenitor cells such
as human CD34+ cells. Packaged defective viral genomes were passaged serially in fibroblasts and
could be detected at passage 3; however, the copy number appeared to diminish upon serial
passage. The HCMV amplicon offers an alternative vector strategy useful for gene(s) delivery to
cells of the hematopoietic lineage.
Background
HCMV is a member of the betaherpesvirus family [42,48].
Other members of this family include human herpesvirus
6 (HHV-6), and human herpesvirus 7 (HHV-7), and all
are widely distributed in human populations. During pro-
ductive replication, the 230 kilobase pair (kbp) viral
genome replicates by a rolling circle mechanism, which
generates long head-to-tail concatemers that are cleaved
to unit length and packaged in capsids. The state of the
HCMV genome during latency remains unidentified and
is likely to be circular and extrachromosomal [6]. The
HCMV genome has been detected in cells within the
hematopoietic lineage as early as CD34+ progenitors and
up through differentiated macrophages [23,29,38,54].
Defective HSV viruses created by high multiplicity serial
passage of virus stocks have been described on numerous
occasions and have been characterized in detail at the
molecular level [13,18,31,43,52,67]. Naturally occurring
defective HSV viruses and laboratory derived HSV ampli-
con vectors are composed of head-to-tail tandem reitera-
tions of subgenomic regions containing a functional
origin of DNA replication (OriSor OriL) and a DNA cleav-
age/packaging signal [3,4,30,57,60-62]. These two cis-act-
ing functions can be relatively small ranging from ca. 90–
150 base pairs (bp) for the ori and ca. 250–300 bp for the
a sequence. The functional HCMV oriLyt is much more
complex than either of the HSV oris; the HCMV oriLyt
consists of multiple direct and inverted repeats and
extends over at least 1500 bp [1,2,24,37]. HCMV is
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unique among the herpesviruses in not having an origin
binding protein homolog that is required for DNA repli-
cation [45]. The HCMV a sequence varies in size from ca.
550 bp to 762 bp, however, the conserved pac-1 and pac-
2 cis-elements which determine the sites for cleavage of
replicated viral DNA are present [15,28,58,64,65].
In contrast to HSV, HCMV does not efficiently produce
defective virus genomes, this difference may be related to
the distinct biology of the two viruses [45]. However two
reports described the identification of what may poten-
tially be HCMV defective viruses created by serial high
multiplicity passage [47,59]. These reports characterized
HCMV defectives as very large subgenomic DNA mole-
cules, in some cases extending over two thirds of the
genome. In addition to these replication defective HCMV
viruses, a recent report by Borst et al. 2003 [7], described
the construction of an HCMV amplicon. In this report we
further utilized the HCMV amplicon for gene delivery to
human CD34+ cells.
HCMV infects cells of the hematopoietic lineage
[34,38,39,55,68]. Viral genomes can be found in CD34+
cells from seropositive individuals and granulocyte-mac-
rophage progenitors and differentiated macrophages can
be infected experimentally [56]. We were interested in
determining whether the tropism of HCMV can be
exploited to construct defective HCMV virus vectors
(amplicons) targeted to hematopoietic stem cells. The
general feasibility of such an approach for other cell types
has been shown using other herpesviruses, e.g. HSV, EBV,
and HHV-7 [20,25,26,30,35,49,70,71].
Methods
Cells and virus
HCMV Toledo (passage 8, from Dr. S. Plotkin, Aventis
Pasteur, Doylestown, PA), and HCMV TownevarRIT (pas-
sage 134, from Dr. Plotkin via Dr. Ed Mocarski, Stanford
University), were propagated in human fibroblasts (HF)
cultured in Dulbecco's modified Eagle's medium supple-
mented with 10% fetal calf serum (JRH Biosciences, Len-
exa, Kans.). Recombinant HCMV, RC2.7EGFP, expressing
enhanced green fluorescent protein (EGFP) (Clonetech,
Palo Alto, CA), under the control of the major early 2.7
promoter, was constructed by cotransfection of plasmid
pEAG2.7EGFP with a set of overlapping cosmid clones
derived from HCMV Toledo (G.M. Duke, unpublished
data).
Plasmid constructions
Plasmid pON205 (Spaete and Mocarski, 1985), contains
the Towne strain a  sequence, was obtained from Ed
Mocarski (Stanford University). pEAG2.7EGFP was
derived by cloning the EGFP gene from plasmid pEGFP-
N2 (Clonetech, Palo Alto, CA) between the EagI and SmaI
site of the β2.7 gene taken from Toledo (G.M. Duke,
unpublished data). HCMV amplicon plasmid Tn9-8 was
derived by inserting the 6 kpb DraI fragment of Townevar-
RIT (corresponding to nucleotides 91,166 – 95,909 rela-
tive to AD169) (Figure 1B), spanning the HCMV oriLyt
into the EcoRI site of pON205. Tn9-8 was partially
sequenced by single-cycle and multicycle dideoxy-nucle-
otide chain termination method of Sanger et al., [51]. The
plasmids designated Tn9-8GF5 and Tn9-8GF7 incorporat-
ing the EGFP gene with the HCMV Major Immediate Early
(MIE) promoter and SV40 poly A sequence was isolated as
a 2,334 bp NsiI fragment from plasmid pEGFP-N2
(Clonetech, Palo Alto, CA), and cloned into the HCMV
amplicon Tn9-8 at the PstI site in both orientations. The
gpt gene in Tn9-8-gpt was derived by cloning a PCR frag-
ment from Escherichia coli DH5α using the primer pairs
5'CTGCAGCTAGTCTAGACTGGGACACTTCACATGAGC
3'and
5'CTGCAGCTATGTATCTAGAGCCAGGCGTTGAAAAGAT
TA3'.
Generation of viral stocks containing amplicons
Plasmid DNA was transfected by CaPO4 precipitation of
approximately 4 µg of Tn9-8 amplicon DNA. The Tn9-8
DNA was transfected into approximately 1 × 106 passage
16 human fibroblast (HF) cells. At 24 hours post transfec-
tion, the cells were infected with CMV Towne at a multi-
plicity of infection (MOI) of 5 plaque forming units
(PFU) per cell. Fresh medium was added to cells four days
after infection and cells were harvested at 6 to 7 days post
infection as described previously (Spaete and Frenkel,
1982). Virus stocks are prepared by three freeze-thaw
cycles. Serial passages of amplicon-containing viral stocks
on fresh HF cells were superinfected with CMV Towne as
a helper virus at a MOI of 1.
Southern blot analysis
Viral DNAs were digested with restriction enzyme, electro-
phoresed in 0.8% agarose gels, transferred to Hybond-N+
nylon membranes (Amersham Corp.), (Maniatis et al.,
1989), and immobilized with a UV Crosslinker 1000
(Hoefer Scientific Instruments, San Francisco, CA). DNA
on the membrane was probed with fluorescein-labeled
pUC9 DNA using conditions previously described (Spaete
and Mocarski, 1985).
Isolation of CD34+ cells and infection with CMV
The isolation of cord blood CD34+ stem cells was carried
out by All Cells Inc. (Berkeley, CA) using CD34 Progenitor
Cell Isolation Kit (Miltenyi Biotech, Auburn, CA). The
positive selection of the CD34+ cells was carried out using
hapten-conjugated antibody to CD34+ followed by anti-
hapten antibody coupled to MACS Microbeads. The mag-
netically labeled cells are enriched on positive selection
columns in the magnetic field. The purity of the CD34+Genetic Vaccines and Therapy 2005, 3:1 http://www.gvt-journal.com/content/3/1/1
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population was >95% as analyzed by flow cytometry. The
purified CD34+ cells were suspended in Iscove's modified
Dulbecco's Minimal Essential Medium containing 5%
fetal bovine serum. 2 × 105 CD34+ cells were used for each
infection with TN9-8GF5 amplicon containing stocks,
RC2.7EGFP virus, CMV Towne virus, or uninfected cell
control. The cells mixed with virus were centrifuged at 500
× g for 10 mins at room temperature and were then placed
in 37°C water bath for one hour. Following this the cells
were cultured in 6-well cell culture plates (Costar) for 18–
72 hours. At the end of the incubation the cells were har-
vested for CD34 staining.
EGFP expression and immunostaining for flow cytometric 
analysis
Amplicon containing viral stocks prepared from passage 1
were used to infect HF or human CD34+ cells maintained
in 12 well culture plates. At 24 hour intervals post infec-
tion, the wells were observed for EGFP expression with a
Nikon TE2000 microscope under UV illumination.
Immunostaining for CD34+ cells was done using Phyco-
erythrin (PE)-conjugated anti-CD34 antibody (Becton
Dickinson, San Jose, CA). Infected or control cells were
incubated with 20 µl of PE-labeled anti-CD34 antibody
for 45 minutes at room temperature and subsequently
were washed twice with PBS containing 0.1% BSA. The
cells were directly analyzed for EGFP and CD34+ staining
on a FACSCalibur instrument (Becton Dickinson, San
Jose, CA), at 18 and 36 hours post infection.
Results
In order to exploit the natural tropism of HCMV for cells
of the hematopoietic lineage, in a nonlytic manner, an
HCMV amplicon i.e. a plasmid containing the HCMV ori-
Lyt and a sequences was constructed. Theoretically, due to
the large size of the HCMV genome, an amplicon derived
Schematic representation of amplified region near oriLyt of the HCMV genome Figure 1
Schematic representation of amplified region near oriLyt of the HCMV genome. A. Restriction enzyme map of minimal oriLyt 
and adjacent region of heterogeneity (block). B. Region of heterogeneity shown as a dimer. Arrow indicates junction of the 
repeat segment. The number 91,166 to the left of the restriction map corresponds to the nucleotide position of the AD169 
genome (EMBL accession number X17403). C. Autoradiograph of Southern blot utilizing a minimal oriLyt probe, pON2623 
(Kemble et al., 1996). Monomers and dimers are depicted with one and two arrows, respectively. Trimers and tetramers can 
be seen in the TownevarRIT viral stock.
minimal oriLyt
DraI
DraI
91,166
PvuI
MluI
EcoRI V/E
BamHI
BamHI
MluI
SacI
SacI
KpnI
BglII
NaeI
A.
95,909
DraI
DraI
91,163
PvuI
MluI
EcoRI V/E
BamHI
BamHI
MluI
SacI
SacI
KpnI
BglII
NaeI
B.
SacI
KpnI
BglII
NaeI
probe:  pON2623
C.
TownevarRIT
TownevarMAGenetic Vaccines and Therapy 2005, 3:1 http://www.gvt-journal.com/content/3/1/1
Page 4 of 11
(page number not for citation purposes)
from this virus should be able to carry the large DNA
inserts and be capable of efficient introduction into
hematopoietic cells by infection.
Heterogeneity at oriLyt
During analysis of cosmid clones of HCMV strain Towne,
sequence heterogeneity was observed in the EcoRI E frag-
ment of Towne that was not present in the Toledo strain
[27]. The EcoRI E region spans in part the complex oriLyt
region [1,2,24,37]. Sequences in a 1.2 kbp repeat frag-
ment were shown to give rise to the heterogeneity
observed at this locus in the Towne genome (Figure 1).
The coordinates of a single repeat unit starts at nucleotide
94,561 relative to the AD169 sequence and end at nucle-
otide 95,807 [10]. This segment can repeat at least three
times in Towne strains from different passage histories
(Fig. 1). This heterogeneity is different from the 189 bp
repeat region previously described for the Towne strain
oriLyt which occurs near the BamHI sites in Figure 1 (nt
93337–93525 relative to AD169), [11,12]. Since Towne
replicates to relatively high titers in cell culture, it was
deemed advantageous to incorporate this heterogeneity in
the origin containing sequences to be used in the ampli-
con construct.
Construction of the HCMV amplicon
As a test of the feasibility of the system, an HCMV ampli-
con was constructed which incorporated the two cis-acting
functions required for the propagation of the defective
virus genomes in the presence of helper virus (Figure 2).
HCMV amplicon plasmid Tn9-8 was derived by inserting
the 6 kpb DraI fragment of Towne (corresponding to
nucleotides 91,166–95,909 relative to AD169) [10] (Fig-
ure 1B), spanning the HCMV oriLyt into the EcoRI site of
pON205. The resulting amplicon was designated Tn9-8
(Figure 2), and was partially sequenced to verify its
structure.
Generation of viral stocks containing amplicons
As a test of the ability of this construct to function as an
amplicon, plasmid Tn9-8 was transfected in human
fibroblast (HF) cells, and subsequently infected with
HCMV Towne strain at an MOI of 5 to provide helper
virus replication functions. Seven days later, infected cells
were harvested, sonicated, and viral stocks were prepared
for passage to fresh HF cells. Fresh HF cells were infected
with the progeny of the transfection/infection and incu-
bated for 7 days. The DNA from these infected cells was
harvested (designated passage 1), restricted with HindIII
and DpnI, and Southern blotted [36]. Southern blot anal-
yses of DNA demonstrated that Tn9-8 was susceptible to
digestion with DpnI, consistent with replication of the
plasmid in bacteria (Figure 3, lane 2). In contrast, Tn9-8
in infected cells was resistant to DpnI demonstrating that
it had replicated in eucaryotic cells (Figure 3, lanes 3–5).
This observation is consistent with replication and pack-
aging of Tn9-8 into infectious virions. These results dem-
onstrate that foreign DNA sequences, exemplified by the
plasmid pUC9, can be introduced into defective genomes
that are packaged and propagated in serially passaged
virus stocks. To examine whether these results were the
consequence of amplicon replication and packaging or
integration of the amplicon plasmid into the helper virus,
DNA prepared from passage 1 infected cells was digested
with Cla I, Xba I, Afl II and Dpn I. These enzymes digested
the Towne helper virus DNA to fragments no larger than
13.6 kbp but do not cut within Tn9-8. The amplicon DNA
was significantly larger than 23 kbp consistent with the
amplicon being replicated as a concatamer (Figure 4).
This result indicated that the high molecular weight DNA
containing plasmid sequences was packaged independ-
ently and was not integrated into helper virus.
Packaged defective viral genomes derived from Tn9-8 or a
derivative containing a selectable marker (Tn9-8-gpt),
were serially passaged in HF cells. Defective viruses could
be detected at passage 3 when probed with plasmid
pUC9; however, the copy number appeared to diminish
upon serial passage (not shown). Selection with myco-
phenolic acid on Tn9-8-gpt amplicons did not enhance
recovery.
Rescue of monomeric repeat units in bacteria
Concatemeric DNA was prepared from passage 2 and 3
virus stocks containing the defective virus genomes (Tn9-
8-gpt), digested with Pst I and Hind III, respectively, in
order to analyze monomeric repeat units. The Hind III-
digested DNA was circularized by ligation and used to
transform E. coli bacteria to analyze structure and to dem-
onstrate shuttle vector capability between eucaryotic and
bacterial hosts. A number of plasmids prepared from the
rescue attempt had a restriction enzyme pattern indistin-
guishable from the input (Fig. 5A, lanes 1 and 2). Other
plasmids however exhibited the expected restriction pat-
tern consistent with a head-to-tail amplification of the a
sequence (lanes 3 and 4). Digestion with NaeI produced a
fragment of the predicted size of a unit length a sequence
(762 bp), and this product hybridized with an a sequence
specific probe (PstI-SgrAI fragment from Tn9-8), (Figs. 2
and 5B, lanes 3 and 4). This type of amplification has
been readily seen in restriction enzyme digested DNA
preparations of parental genomes of both HSV and
HCMV [31,40,41,58,64,69] and has also been observed in
HSV amplicons using Southern blot hybridizations [15].
Expression of heterologous genes in an HCMV amplicon
To demonstrate that the HCMV amplicon could be used
as a vector system to support the expression of a foreign
gene, EGFP under the transcriptional control of the
HCMV major immediate early (MIE) promoter was usedGenetic Vaccines and Therapy 2005, 3:1 http://www.gvt-journal.com/content/3/1/1
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as test reporter gene. Two resulting amplicon plasmids
designated Tn9-8GF5 and Tn9-8GF7 both expressed EGFP
following transfection of HF cells in the absence of helper
virus, as expected (not shown). Packaged amplicons were
generated by introduction of Tn9-8GF5 into cells and
infecting with HCMV 24 hours later at an MOI of 5. Trans-
fection-derived viral stocks were passaged onto fresh HF
cells supplemented with Towne helper virus at an MOI of
1. Viral stocks prepared from passage 1 were used to infect
HF cells and grown on 12-well tissue culture plates. A lim-
ited number (ca. 0. 1%) of brightly fluorescing cells could
be seen by microscopic examination at 24, 72 and 96
Schematic representation of the HCMV amplicon plasmids Tn9-8gpt, Tn9-8GF7 and Tn9-8GF5 Figure 2
Schematic representation of the HCMV amplicon plasmids Tn9-8gpt, Tn9-8GF7 and Tn9-8GF5. The EGFP expression cassette 
was cloned in two orientations in the unique PstI site in Tn9-8. The gpt expression cassette was cloned between the unique PstI 
and HindIII sites.Genetic Vaccines and Therapy 2005, 3:1 http://www.gvt-journal.com/content/3/1/1
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hours post-infection (Figure 6). This demonstrates that a
foreign gene can be expressed in the context of a HCMV
amplicon viral stock in infected HF cells.
To test the utility of the HCMV amplicon in gene therapy
or gene delivery, we used packaged amplicons in viral
stocks to infect and deliver an expressed gene into human
CD34+ progenitor cells. Viral stocks containing ampli-
cons carrying EGFP under the transcriptional control of
the HCMV major immediate early (MIE) promoter pre-
pared from passage 0 and passage 1 were used to infect
CD34+ cells derived from cord blood. Starting at 24 h
after infection, CD34+ cells were examined for EGFP
expression by fluorescent microscopy. EGFP expression
was observed in TN9-8GF5 amplicon-infected CD34+
cells starting at 24 h post-infection. The cells remained
positive for EGFP expression for more than 96 hrs, at
which point the cells were terminated (Figure 6).
In a separate experiment, at 36 hours post infection, the
cells were stained with PE-labeled anti-CD34 and ana-
lyzed for the CD34 marker and EGFP expression. EGFP
expression was observed in the CD34+ population in the
TN9-8GF5 amplicon (0.3%, 0.1%) (Figure 7a, &7b) or the
CMV-EGFP virus (0.6%) (Figure 7c) at 36 hours post
infection. The CMV Towne control-virus infected cells or
uninfected CD34+ cell control were negative for EGFP
expression (Figure 7d, &7e). A small population (7–12%)
of the cells lost expression of the CD34+ marker upon in
vitro  culture. EGFP expression was also observed in a
CD34(-) population infected with either TN9-8GF5
amplicon containing viral stocks (0.8%, 0.1%) or with the
Southern blot analysis of passage 1 of HCMV amplicon DNA  probed with plasmid pUC9 Figure 3
Southern blot analysis of passage 1 of HCMV amplicon DNA 
probed with plasmid pUC9. Lane 1. Plasmid Tn9-8 linearized 
with Hind III serves as a marker for correct migration of 
monomeric repeats. Lane 2. Plasmid Tn9-8 restricted with 
Hind III and Dpn I as a control for non-replicating DNA. 
Lanes 3–5. Infected cell DNAs restricted with Hind III and 
Dpn I. The signal in lanes 3–5 (arrow) demonstrates authentic 
replication and packaging of amplicon Tn9-8 in eucaryotic 
cells.
Southern blot analysis of high molecular weight HCMV ampli- con DNA at passage 1 probed with plasmid pUC9 Figure 4
Southern blot analysis of high molecular weight HCMV ampli-
con DNA at passage 1 probed with plasmid pUC9. DNA pre-
pared from passage 1 infected cells was digested with Cla I, 
Xba I, Afl II and Dpn I, Southern blotted and probed with plas-
mid pUC9. The samples are from those shown in Fig. 3, lanes 
3 and 5. The high molecular weight DNA containing plasmid 
sequences (arrow) demonstrates the major hybridizing spe-
cies migrating slower than the 23 kbp lambda DNA Hind III 
digest indicated as the marker on the left of the 
autoradiograph.Genetic Vaccines and Therapy 2005, 3:1 http://www.gvt-journal.com/content/3/1/1
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CMV-EGFP virus, RC2.7EGFP (3.6%) (Figure 7a, 7b &7c).
The CMV Towne infected cells or uninfected control cell
also had a significant CD34 negative population but were
negative for EGFP expression (Figure 7d, and 7e). These
results clearly demonstrate that CD34+ cells can be
infected with replication competent or incompetent CMV
vectors expressing a foreign gene.
Conclusions
We have shown that a replication-defective virus vector
system that is derived from HCMV is capable of delivering
Tn9-8-gpt was rescued from concatamers following serial passage in HF cells Figure 5
Tn9-8-gpt was rescued from concatamers following serial passage in HF cells. (A) Tn9-8-gpt was passaged in HF cells and mon-
omer units were recovered by linearizing concatemeric DNA from serial passage 3 with HindIII and cloning in bacteria (lanes 2 
and 4) and also by linearizing passage 2 DNA with PstI and cloning in bacteria (lane 3). Lane 1 represents the unpassaged clone 
for comparison. Following rescue in bacteria, DNA was prepared and cut with NcoI. Fragments were separated on an agarose 
gel and visualized with ethidium bromide staining (left panel). The gel was transferred to a nylon membrane and probed with an 
a sequence specific probe (right panel). (B) Fragments from an NaeI digest were also separated on an agarose gel and visualized 
as in panel A. The gel was transferred to a nylon membrane and probed with an a sequence specific probe. Lane 5 shows a 100 
bp ladder. Lanes 3 and 4 show a ca. 800 bp fragment that hybridizes to a sequences.Genetic Vaccines and Therapy 2005, 3:1 http://www.gvt-journal.com/content/3/1/1
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and expressing foreign genes in infected primary cells
including progenitor stem cells such as human CD34+
cells. Further improvement and optimization of the
system offers the potential to deliver gene-based therapies
to multipotent cells.
Advantages for use of the HCMV amplicon
Foremost among the advantages of the vector system we
have described is the potential ability to efficiently infect
and deliver genetic information to hematopoietic stem
cells (CD34+) and other dividing and non-dividing cell
types which may support HCMV infection
[34,38,39,55,68]. Genetic hematological disorders such
as thalassemias and sickle-cell anemia and other hema-
globinopathies could therefore be targeted for therapy
with this strategy. Another potential advantage for the sys-
tem is that vector DNA could possibly be maintained as
an episome with minimal concern for the potential con-
sequences of random integration of vector DNA (i.e. acti-
vation of oncogenes or inactivation of tumor suppressor
genes). In order to insure efficient segregation as an epi-
some, the EBV latent replication origin, oriP, and the
transactivator, EBNA-1, could be added as was previously
shown for another hybrid herpesvirus vector [71]. How-
ever such a modification may not be necessary because
HCMV genomes appear to be carried continuously in cells
of hematopoietic origin in infected individuals. Yet
another potential advantage as with other herpesviral vec-
tors, is that the HCMV vector system should have the
capacity for very large inserts.
Infection of CD34+ cells with HCMV
The infectivity of CD34+ cells from seropositive and
seronegative subjects with HCMV has been tested both in
vivo and in vitro [53]. Furthermore, hematopoietic stem
cells are also reported as a site for HCMV latency. Efficient
transduction of human CD34+ cells with retroviral and
non-viral vectors has been unsatisfactory due to the lack of
maintenance of high levels of expression of the transgene
following engraftment of the engineered cells [16]. The
HCMV MIE promoter may not be the right promoter for
optimal expression in a CD34+ cells, since it has been
shown that in the context of a lentiviral-based gene trans-
fer system this promoter appeared to function less
Fluorescent Microscopic Analysis of TN9-8GF5 amplicon infected cells Figure 6
Fluorescent Microscopic Analysis of TN9-8GF5 amplicon infected cells. Human fibroblast cells (HF) or human cord blood 
CD34+ cells were infected with TN9-8GF5 amplicon-containing stocks, or mock infected. Cells were observed at different 
time-points 24, 72 and 96 hrs post infection with TN9-8GF5 amplicon under the fluorescent microscope (Nikon TE2000 
microscope). EGFP expressing fluorescent cells were observed in the TN9-8GF5 amplicon infected human fibroblast cells or 
human CD34+ cells at different time-points. Control uninfected cells were negative (not shown).
Human
Fibroblasts
Human
CD34+
72 h 96 h 24 h Genetic Vaccines and Therapy 2005, 3:1 http://www.gvt-journal.com/content/3/1/1
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efficiently due to a cell-type specific expression defect
[16]. The approaches to improving the efficiency of gene
transfer into human cells have focused on improving gene
delivery vectors and optimizing ex vivo culture conditions,
which preserve the developmental properties of the stem
cells [14,22]. Umbilical cord blood is recognized as a rich
source of hematopoietic CD34+ stem cells [33]. In our
experiments we used cord blood derived CD34+ cells for
infection with HCMV amplicon containing stocks or
HCMV-EGFP virus. However, bone marrow derived
CD34+ cells have also been shown to be infectable in vitro
with HCMV [34]. Gentry & Smith [21], reported a progres-
sive loss of primitive cell properties including a reduction
of CD34 expression upon in vitro culture of cord blood
derived CD34+ cells. In a separate study, cord blood
derived CD34+ cells cultured with IL-3 in vitro showed a
progressive decline of the CD34+ population and more
differentiated cells originating in the CD34(-) population
[9]. In our experiments with >95% pure cord blood
derived CD34+ cell population, a loss of CD34 expression
in a small percent population (9–12%) of stem cells upon
in vitro culture has been observed. EGFP expression was
also seen in the CD34(-) population (Fig 7a, 7b, &7c). It
is possible that HCMV infection of CD34 cells could
Flow cytometry analysis of human cord blood CD34+ cells infected with CMV amplicon containing stocks, virus, or uninfected  cell control Figure 7
Flow cytometry analysis of human cord blood CD34+ cells infected with CMV amplicon containing stocks, virus, or uninfected 
cell control. TN9-8GF5 amplicon (a,b), CMV-EGFP (RC2.7EGFP) virus (c), CMV (Towne) infected (d), or control uninfected 
human cord blood CD34 cells (e,f), were stained 36 hours post-infection with PE-antiCD34 antibody (a-e), or were left 
unstained (f), and were analyzed for two-color cytometry analysis using a FACS Calibur instrument. The dot-plots are gener-
ated using Cell Quest software and reveal the EGFP+ cells populations. Numbers in the upper right and lower right quadrants 
indicate percentage of the EGFP+CD34+ and EGFP+CD34- cells respectively. A frequency lower than 0.01% is considered 
negative.Genetic Vaccines and Therapy 2005, 3:1 http://www.gvt-journal.com/content/3/1/1
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induce cell differentiation and loss of primitive properties
including reduction of CD34 expression.
Further studies of HCMV infection in CD34 cells will help
in defining whether CD34+ infected cells undergo cell dif-
ferentiation by increased expression of other markers such
as CD33, CD38, HLA-DR or cytokines. It is also relevant
to note here that HCMV virus carries homolog sequences
for HLA-related and cytokine-related molecules and infec-
tion can induce cellular cytokines
[5,8,19,32,44,46,50,66]. The HCMV amplicons contain
only the cis-acting ori and packaging sequences, and have
no structural gene sequences. However, amplicon con-
taining viral stocks are a mixture with HCMV replication
competent helper virus. HCMV induced cell-differentiat-
ing effect, if any, might be minimized using a helper virus-
free amplicon system. In this regard, it should be possible
to test a number of strategies to prepare helper virus-free
stocks [17,63]. These preparations would be useful for
therapeutic applications in immuno-compromised
patients.
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